The company
AnaCardio is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
The funding
AnaCardio, based in Stockholm, Sweden, announced €62.5M in Series B financing on September 30, 2026.
Participants include Helsinn Investment Fund, Pureos Bioventures, Flerie Invest, Novo Holdings, Sound Bioventures, Innovestor Life Science Fund, LLD Nybohov Invest AB, Ljungström family office, Industrifonden.